Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.

"Declarations Ethical approvalTumour samples assembled from UK-CCLG institutions were provided as part of the CCLG approved biological study BS-2007-04. Human tumour investigations were conducted with approval from Newcastle/North Tyneside Research Ethics Committee (study reference 07/Q0905/71). Informed consent was obtained for all patients. Competing of interestsS.M.P. reports grants or contracts from ITCC-P4 companies; Lilly, Roche, Pfizer, Charles River, Bayer HealthCare, Pharma Mar, Amgen, Sanofi, Astra Zeneca and Servier. S.Ru. reports participation on advisory boards for Bayer (Germany), Roche (Germany), BMS (Germany) and data safety monitoring board for Cellgene (USA). All other authors declare no competing interests. Competing of interests S.M.P. reports grants or contracts from ITCC-P4 companies; Lilly, Roche, Pfizer, Charles River, Bayer HealthCare, Pharma Mar, Amgen, Sanofi, Astra Zeneca and Servier. S.Ru. reports participation on advisory boards for Bayer (Germany), Roche (Germany), BMS (Germany) and data safety monitoring board for Cellgene (USA). All other authors declare no competing interests."

"This study was funded by Cancer Research UK (CRUK/23391 and a PhD studentship from the CRUK Newcastle Centre) and Children’s Cancer North. We acknowledge the SIOP-E Brain Tumour Group (Embryonal Tumour and Neurosurgery Special Interest Groups). S.Ru. acknowledges support from the German Children’s Cancer Foundation, Bonn."